title: Suppression of peritoneal thickening by histamine in a mouse model of peritoneal scraping.
abstract: BACKGROUND
  Inflammatory reactions play an important role in peritoneal sclerosis in patients on peritoneal dialysis. Since histamine affects inflammatory reactions and immune responses, we investigated effects of intraperitoneal administration of histamine on peritonitis induced by mechanical scraping in mice.
  
  
  METHODS
  After anesthesia, the right peritoneum was scraped 90 times over 1 min, and bilateral peritonea were observed by light microscopy after 7 days.
  
  
  RESULTS
  Thickness of the peritoneal membrane on the right side was 174 ± 77 µm (mean ± SD, n = 8), while that on the left side was 24 ± 19 µm. Intraperitoneal administration of histamine (0.3 or 1.0 mmol/L, 0.5 mL each) twice daily for 7 days after scraping decreased thickness of the right peritoneum to 42 and 43 % of that in saline-injected animals, respectively (P < 0.01), although histamine (0.1 mmol/L) did not affect it. Promethazine (5 nmol, twice daily for 7 days), a histamine H1 receptor antagonist, abolished the amelioration caused by histamine (1.0 mmol/L). Neither ranitidine (15 nmol), a histamine H2 receptor antagonist, nor thioperamide (7.5 nmol), a histamine H3/H4 receptor antagonist, affected the outcome in histamine-treated mice.
  
  
  CONCLUSIONS
  These findings indicate that histamine H1 action partly prevents the development of peritoneal fibrosis caused by mechanical scraping.
authors.affiliation: Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558, Japan.
authors.forename: Keyue
authors.initials: K
authors.lastname: Liu
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Yorozuya
authors.forename: Naoto
authors.initials: N
authors.lastname: Adachi
authors.forename: Atsuko
authors.initials: A
authors.lastname: Motoki
authors.forename: Kanji
authors.initials: K
authors.lastname: Ninomiya
authors.forename: Hisao
authors.initials: H
authors.lastname: Mabuchi
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Iwamoto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nishibori
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D006632:Histamine / Q000627:therapeutic use*; D017442:Histamine Agonists / Q000627:therapeutic use*; D006633:Histamine Antagonists; D007274:Injections, Intraperitoneal; D008297:Male; D008810:Mice, Inbred C57BL; D056627:Peritoneal Fibrosis / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control; D010537:Peritoneum / Q000473:pathology; D010538:Peritonitis / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D011897:Random Allocation
chemical_list: D017442:Histamine Agonists; D006633:Histamine Antagonists; D006632:Histamine